Leuprolide (Lupron / Eligard): GnRH Agonist for Prostate Cancer, Endometriosis, and CPP — Research Overview

Leuprolide acetate (brand names Lupron, Lupron Depot, Eligard, and others) is a synthetic nonapeptide analog of gonadotropin-releasing hormone (GnRH), also called luteinizing hormone-releasing hormone (LHRH). It was among the first GnRH agonists approved by the FDA, receiving initial approval in 1985 for advanced prostate cancer. Today it remains a cornerstone of androgen-deprivation therapy (ADT) and is also approved for endometriosis, uterine fibroids, and central precocious puberty. Its central pharmacological paradox — that continuous agonism at the GnRH receptor downregulates, rather than stimulates, gonadotropin secretion — took decades of basic research to unravel and forms the basis of its clinical utility.

What Is Leuprolide?

Leuprolide is a synthetic GnRH analog consisting of nine amino acids. It was developed by Takeda Pharmaceutical Company and co-developed in the United States with TAP Pharmaceuticals (a Takeda-Abbott joint venture). The peptide retains the core GnRH sequence but incorporates a D-leucine amino acid at position 6 and an ethylamide modification at the C-terminus. These substitutions confer resistance to endopeptidase cleavage and a substantially longer receptor-binding duration compared with native GnRH, which has a half-life of only a few minutes.

Multiple formulations exist: the original daily subcutaneous injection (Lupron), monthly and 3-month depot intramuscular injections (Lupron Depot), a 4-month and 6-month depot IM formulation, and a subcutaneous in-situ-forming depot (Eligard, available in 1-, 3-, 4-, and 6-month durations). Pediatric depot formulations (Lupron Depot-Ped) are specifically labeled for central precocious puberty.

Mechanism of Action

GnRH is normally released in pulses from the hypothalamus, and these pulses are required for normal pituitary responsiveness. Each pulse stimulates pituitary gonadotrophs to release luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn stimulate gonadal production of testosterone in men and estrogen in women.

Leuprolide, when administered continuously rather than in pulses, persistently occupies GnRH receptors. After an initial "flare" of LH and FSH release (lasting days to a few weeks), the GnRH receptors are progressively downregulated and desensitized. This leads to a marked fall in LH and FSH, and consequently to a profound reduction in gonadal steroid production — castrate levels of testosterone in men, and estradiol suppression in women. This pharmacological castration is reversible upon discontinuation.

The initial testosterone "flare" can cause transient clinical worsening in prostate cancer patients ("tumor flare"), which is clinically important in patients with vertebral metastases or urinary obstruction. Short-course antiandrogen co-administration (flare protection) is typically used in these settings.

What the Research Shows

The initial pivotal trials for leuprolide in advanced prostate cancer demonstrated that daily subcutaneous injection consistently suppressed serum testosterone to castrate levels (< 50 ng/dL) and produced objective tumor responses comparable to orchiectomy. These trials, conducted in the early 1980s through Takeda and TAP Pharmaceuticals, supported the 1985 FDA approval.

Development of depot formulations expanded the evidence base considerably. A PMC review of the clinical development of leuprolide acetate depot formulations (Padula et al. 2023, PMC10201295) documented the progression from monthly 7.5 mg IM depot through the 22.5 mg 3-month, 30 mg 4-month, and 45 mg 6-month formulations, each validated in dedicated Phase II/III trials for testosterone suppression duration and tumor control. The 6-month 45 mg IM depot formulation received FDA approval for prostate cancer, and the FDA label for this formulation (NDA 020708) is available on accessdata.fda.gov.

For endometriosis, randomized controlled trials comparing leuprolide depot to danazol and placebo established significant reduction in pain scores and endometriotic lesion size. For central precocious puberty (CPP), leuprolide depot suppresses LH and sex steroid levels and effectively arrests premature puberty progression, with return of gonadal function after cessation. Multiple prospective trials in pediatric populations documented near-normal adult height outcomes with appropriate treatment duration.

Long-term safety data for ADT with leuprolide identify well-characterized risks including bone mineral density loss, hot flashes, metabolic syndrome, cardiovascular effects, and sexual dysfunction. These are described in detail in current FDA labels for all formulations.

Pharmacokinetics

The pharmacokinetics of leuprolide vary substantially by formulation. The daily subcutaneous injection achieves peak plasma concentrations within 2–6 hours (Tmax) with a terminal half-life of approximately 3 hours. Bioavailability is approximately 90% by subcutaneous route.

Depot formulations exploit a sustained-release polymer matrix (PLGA microspheres for Lupron Depot; an in-situ-forming ATRIGEL polymer for Eligard) that provides controlled leuprolide release over weeks to months. Following the initial burst, steady-state plasma concentrations sufficient for gonadotropin suppression are maintained for the labeled duration. Testosterone suppression onset typically occurs within 2–4 weeks of the first injection. No dose adjustment for renal or hepatic impairment is specified in the FDA labels for currently approved depot formulations.

Approved Indications and Clinical Dose Ranges

Not medical advice. These are ranges reported in research literature, not personalized recommendations. Consult your physician.

Leuprolide is FDA-approved for the following indications. For advanced prostate cancer: The FDA labels specify various depot formulations — the 1-month Lupron Depot 7.5 mg IM, 3-month 22.5 mg IM, 4-month 30 mg IM, and 6-month 45 mg IM; Eligard 7.5 mg SC monthly, 22.5 mg SC 3-monthly, 30 mg SC 4-monthly, and 45 mg SC 6-monthly. For endometriosis: The label specifies Lupron Depot 3.75 mg IM monthly or 11.25 mg IM every 3 months, limited to 6 months of therapy with the possibility of one additional 6-month course. For uterine fibroids (preoperative): The label specifies Lupron Depot 3.75 mg monthly for up to 3 months or 11.25 mg as a single dose.

For central precocious puberty: The Lupron Depot-Ped label specifies weight-based dosing (starting at 0.3 mg/kg IM every 4 weeks for children ≥25 kg, with specified fixed doses for lower weight bands). For the daily subcutaneous injection: The Lupron injection label specifies 1 mg SC once daily for advanced prostate cancer. All dose decisions for individual patients rest with the prescribing clinician.

Storage and Handling

Lupron Injection (daily SC) should be stored below 25°C (77°F) and protected from light and freezing. Lupron Depot microsphere kits are stored at room temperature below 25°C, and the reconstituted suspension should be administered immediately after mixing. Eligard two-syringe kits are stored in the refrigerator at 2–8°C (36–46°F) and should be brought to room temperature before administration. All leuprolide products are single-dose; unused portions must be discarded.

What Leuprolide Is NOT

Leuprolide is frequently confused with GnRH antagonists such as degarelix (Firmagon) and relugolix (Orgovyx). Although both drug classes suppress testosterone in prostate cancer, the mechanism differs fundamentally: GnRH antagonists competitively block the GnRH receptor without an initial flare, achieving faster testosterone suppression without the risk of tumor flare. Leuprolide is a GnRH agonist and will cause a transient testosterone rise in the first 1–2 weeks.

Leuprolide should not be confused with other GnRH analogs used in fertility medicine such as buserelin, triptorelin, or histrelin, which have overlapping but distinct indication profiles. It is also not a gonadotropin (i.e., it is not LH or FSH, and it does not stimulate ovulation at the doses used for hormone suppression). The word "leuprorelin" is used in many countries and refers to the same molecule.

References

1. Padula GDA, et al. Clinical development of the GnRH agonist leuprolide acetate depot. PMC10201295. 2023.

2. U.S. FDA. Lupron Depot (leuprolide acetate for depot suspension) Prescribing Information. NDA 019732/020517. Updated 2025.

3. U.S. FDA. Lupron Depot-Ped (leuprolide acetate for depot suspension) Prescribing Information. NDA 020263. Updated 2025.

4. Crawford ED, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med. 1989;321(7):419–424.